Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies.

IF 2.5 3区医学 Q3 PHARMACOLOGY & PHARMACY

Expert Opinion on Pharmacotherapy Pub Date : 2024-06-01 Epub Date: 2024-07-10 DOI:10.1080/14656566.2024.2374464

Mengdi Zhang, Zhiqiang Wang, Changhai Ding

{"title":"Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies.","authors":"Mengdi Zhang, Zhiqiang Wang, Changhai Ding","doi":"10.1080/14656566.2024.2374464","DOIUrl":null,"url":null,"abstract":"Introduction: Osteoarthritis (OA) related pain has affected millions of people worldwide. However, the current pharmacological options for managing OA-related pain have not achieved a satisfactory effect.Areas covered: This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.Expert opinion: Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2374464","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Osteoarthritis (OA) related pain has affected millions of people worldwide. However, the current pharmacological options for managing OA-related pain have not achieved a satisfactory effect.

Areas covered: This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.

Expert opinion: Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.

查看原文本刊更多论文

骨关节炎相关疼痛的药物疗法：现有疗法和新兴疗法。

导言：骨关节炎（OA）相关疼痛影响着全球数百万人。然而，目前用于治疗 OA 相关疼痛的药物并未取得令人满意的效果：本综述概述了治疗 OA 相关疼痛的现有药物和新兴药物。内容包括药物的作用机制、安全性、有效性和局限性。主要检索了美国国家医学图书馆（PubMed）数据库2000年至2024年的数据：专家观点：目前治疗 OA 疼痛的方案有限，且效果不佳。外用非甾体抗炎药（NSAIDs）是公认的治疗 OA 相关疼痛的一线药物，其他药物在指南中的推荐并不一致。神经生长因子（NGF）抑制剂、离子通道抑制剂和降钙素基因相关肽（CGRP）拮抗剂等新出现的治疗方案有望用于治疗 OA 相关疼痛。此外，抗抑郁药和抗癫痫镇痛药的再利用也为治疗 OA 相关疼痛带来了曙光。由于疼痛具有异质性和主观性，因此治疗 OA 相关疼痛具有挑战性。我们需要考虑采取更全面的策略，结合非药物疗法，为患者量身定制个性化的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Pharmacotherapy 医学-药学

CiteScore

5.60

自引率

3.10%

发文量

163

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.